Clinical Study Protocol for the Treatment of ND-AML and RR-AML With KMT2A Gene Abnormalities Using VHEA.
Status:
RECRUITING
Trial end date:
2027-12-30
Target enrollment:
Participant gender:
Summary
This study is a clinical trial aimed at evaluating the efficacy and safety of the VHEA（Venetoclax with Homoharringtonine，Etoposide，Cytarabine）regimen in the treatment of newly diagnosed and relapsed/refractory acute myeloid leukemia (AML) with MLL gene abnormalities.
This study includes the induction and consolidation phases of AML treatment.
Phase:
NA
Details
Lead Sponsor:
Huai'an First People's Hospital
Collaborators:
The Affiliated Hospital of Xuzhou Medical University The First People's Hospital of Changzhou Zhenjiang First People's Hospital